Valneva (NASDAQ:VALN) Shares Gap Down – Here’s What Happened

Posted by Francis Steltz on Aug 24th, 2026

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN – Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $6.96, but opened at $6.68. Valneva shares last traded at $6.6450, with a volume of 3,874 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on VALN. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. Wall Street Zen raised Valneva from a “strong sell” rating to a “sell” rating in a research note on Monday, June 1st. Finally, TD Cowen began coverage on Valneva in a research note on Tuesday, August 11th. They issued a “buy” rating and a $12.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $11.98.

View Our Latest Stock Analysis on Valneva

Valneva Stock Down 2.9%

The company has a quick ratio of 1.69, a current ratio of 2.16 and a debt-to-equity ratio of 2.04. The stock has a 50 day simple moving average of $5.40 and a 200 day simple moving average of $6.82. The stock has a market cap of $641.08 million, a price-to-earnings ratio of -3.20 and a beta of 1.77.

Valneva (NASDAQ:VALN – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.21). Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%.The firm had revenue of $39.37 million for the quarter, compared to analyst estimates of $44.17 million. As a group, analysts expect that Valneva SE Sponsored ADR will post -1.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new stake in Valneva in the fourth quarter worth $44,000. Marex Group plc purchased a new position in shares of Valneva during the 2nd quarter valued at $64,000. XTX Topco Ltd purchased a new position in shares of Valneva during the 4th quarter valued at $94,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Valneva during the 3rd quarter worth $124,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

(Get Free Report)

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.